- Home
- NUVL vs PB Comparison
NUVL vs PB Comparison
Compare NUVL & PB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NUVL
- PB
- Stock Information
- Founded
- NUVL 2017
- PB 1983
- Country
- NUVL United States
- PB United States
- Employees
- NUVL N/A
- PB N/A
- Industry
- NUVL Biotechnology: Pharmaceutical Preparations
- PB Major Banks
- Sector
- NUVL Health Care
- PB Finance
- Exchange
- NUVL Nasdaq
- PB Nasdaq
- Market Cap
- NUVL 5.6B
- PB 6.1B
- IPO Year
- NUVL 2021
- PB 1998
- Fundamental
- Price
- NUVL $73.48
- PB $67.17
- Analyst Decision
- NUVL Strong Buy
- PB Buy
- Analyst Count
- NUVL 8
- PB 14
- Target Price
- NUVL $115.50
- PB $83.54
- AVG Volume (30 Days)
- NUVL 682.1K
- PB 728.4K
- Earning Date
- NUVL 05-08-2025
- PB 04-23-2025
- Dividend Yield
- NUVL N/A
- PB 3.43%
- EPS Growth
- NUVL N/A
- PB 20.96
- EPS
- NUVL N/A
- PB 5.23
- Revenue
- NUVL N/A
- PB $1,212,807,000.00
- Revenue This Year
- NUVL N/A
- PB $12.40
- Revenue Next Year
- NUVL N/A
- PB $7.82
- P/E Ratio
- NUVL N/A
- PB $12.93
- Revenue Growth
- NUVL N/A
- PB 11.62
- 52 Week Low
- NUVL $55.54
- PB $57.16
- 52 Week High
- NUVL $113.51
- PB $86.76
- Technical
- Relative Strength Index (RSI)
- NUVL 54.91
- PB 46.17
- Support Level
- NUVL $71.60
- PB $65.74
- Resistance Level
- NUVL $74.28
- PB $69.11
- Average True Range (ATR)
- NUVL 4.86
- PB 2.64
- MACD
- NUVL 1.08
- PB 0.48
- Stochastic Oscillator
- NUVL 95.73
- PB 74.27
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.
About PB Prosperity Bancshares Inc.
Prosperity Bancshares Inc provides retail and commercial banking services to individuals and small to midsize businesses. It provides a wide array of financial products and services to businesses and consumers throughout Texas and Oklahoma. The group provides Personal, Business, Mortgage, and Banking Services.